2003 Immune Response Therapies 
Drug Target Review
NOVEMBER 17, 2023
NK cells are among the front line of protection from infected and abnormal cells as part of the ‘innate immune response’. They recognise ‘cell stress molecules’ on the surface of infected, old, injured and cancerous cells without the need for complex pre-stimulation signals of the adaptive immune system (eg, T cells).
Drug Target Review
FEBRUARY 28, 2024
Over the past 25 years, T-cell therapies have gained significant ground in the treatment of cancer. Preclinical research on γδ T cells has made great strides since the cells were first identified in the 1980s, with γδ T-cell therapies from several companies, including IN8bio, now in or nearing clinical trials for various cancers.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Target Review
OCTOBER 4, 2023
10 Proteasome inhibitors Since the approval of Bortezomib in 2003, 11 new proteasome inhibitors have emerged with reduced side effects. More recently, researchers have begun to look at conjugating immunomodulatory agents to antibodies to directly activate an immune response against the tumour. 1 , 33–43 (2018).
The Pharma Data
NOVEMBER 9, 2020
Cancer immunotherapies such as immune checkpoint inhibitors (ICIs) have shown promising clinical outcomes over the past two decades; and they are often used for patients with advanced cancers once other therapies have reached the end of their effectiveness. NBTXR3 is injected one time, directly into solid tumors. Abstract ID: 410.
NIH Director's Blog: Drug Development
MAY 21, 2020
Just one infusion of this combination antibody therapy lowered the amount of viral genetic material in the animals’ lungs by as much as 30 percent compared to the amount in untreated animals. Meanwhile, there’s been other impressive recent progress towards the development of monoclonal antibody therapies for COVID-19. In the U.S.
The Pharma Data
OCTOBER 19, 2020
NBTXR3 is a novel radioenhancer composed of functionalized hafnium oxide nanoparticles that is administered via one-time intra-tumoral injection and activated by radiation therapy. The physical and universal mode of action (MoA) of NBTXR3 is designed to trigger cellular destruction death and adaptive immune response.
Drug Target Review
FEBRUARY 14, 2025
The KEGG Pathway database provides insights into metabolic pathways, genetic interactions and disease mechanisms, which are crucial for understanding how a dataset can inform our understanding of complex biological phenomena such as signal transduction, cell proliferation, or immune responses.
Expert insights. Personalized for you.
118 
Let's personalize your content